NASDAQ / LIVE COMPANY INTELLIGENCE

Niagen Bioscience, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERNAGE
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / NAGE COVERAGE

What’s moving Niagen Bioscience, Inc. now

Current reporting with the operating signal separated from the noise.

01
Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Investors are testing whether Niagen Bioscience, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

The story matters when it changes Niagen Bioscience, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript

Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript

The story matters when it changes Niagen Bioscience, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

The story matters when it changes Niagen Bioscience, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Niagen Bioscience, Inc. Rings the Nasdaq Stock Market Closing Bell

Niagen Bioscience, Inc. Rings the Nasdaq Stock Market Closing Bell

Investors are testing whether Niagen Bioscience, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

The story matters when it changes Niagen Bioscience, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest NAGE filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-04 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-06 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-03-04 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-04 · Period 2026-08-04SEC ↗8-KMaterial company eventFiled 2026-06-29 · Period 2026-06-24SEC ↗8-KMaterial company eventFiled 2026-05-06 · Period 2026-05-06SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-29 · Period 2026-06-24SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-29SEC ↗
EARNINGS / QUARTERLY TRACKER

Niagen Bioscience, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.